Clinical Phenotyping and Characterization of Neural Networks and Cognitive Processes Involved in Mental Retardation X-linked (XLMR)

July 11, 2017 updated by: Hospices Civils de Lyon

X-linked Mental retardation (XLMR) represent 10% of the causes of mental retardation with a prevalence in both sexes around 1/296, i.e. 3.3 / 1000 births (Opitz et al., 1986). This heterogeneous group of XLMR includes dozens of rare diseases, some of them affecting only a few patients. Molecular diagnosis is currently available in France for 25 XLMR genes, within the national network of XLMR molecular diagnosis. However, whereas some syndromes such as Fragile X syndrome, are now well clinically defined, this is not the case for recently identified syndromes for which very few data is available, preventing clinicians to focus molecular diagnosis on a specific gene.

Therefore, this study aims to :

  • Achieve a description of the clinical phenotype specific to each XLMR gene (Phase 1 of the study, n=200)
  • Characterize the cognitive learning mechanisms and dysfunctional neural networks involved (Phase 2 of the study, n=75, i.e. 5 groups of 15 patients with a mutation in the same gene). These two elements constitute key steps to develop appropriate rehabilitation strategies and targeted pharmacological therapies.

Moreover, the impact of mental retardation on the primary caregiver within the family and the induced burden in terms of psycho-social, organizational and economic burden will also be assessed. These elements, directly related to the patient's environment, are very important to characterize in order to better understand the consequences of each gene mutation (Phase 3 of the study, n=283). For example, it is necessary to better understand the impact of Fragile X syndrome in terms of capacity and behavior, lifestyle, and health care needs of the patients While advancing knowledge allows to consider innovative therapeutics, the implementation of these therapeutics and assessment of their impact on the patients' life trajectory, require precise characterization of the population to be treated in medico socioeconomic terms.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

573

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69500
        • Recruiting
        • Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de neurologie pédiatrique
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 60 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age : from 2 to 60 years old
  • Having a pathogenic mutation of one of the X chromosome genes associated with :

    • For boys : mental retardation (IQ<70), and/or developmental delay (DQ<70) and/or pervasive developmental disorder (autism, Asperger…)
    • For girls : mental retardation (IQ<70), and/or developmental delay (DQ<70) and/or pervasive developmental disorder (autism, Asperger…) and/or specific learning disabilities

Exclusion Criteria:

  • patient or parents refusal to participate in the study
  • genetic polymorphism in a X chromosome gene involved in mental retardation but not considered as pathogenic
  • person refusing to be informed if an abnormality would be discovered during medical examination

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: X-linked Mental retardation
This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.

The assessment includes mainly :

  • The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
  • The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
  • The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
  • The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
  • The Nisonger child behavior rating form which allow to assess the behavior disorders
  • Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
  • Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.
Other: Control Group
This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.

The assessment includes mainly :

  • The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
  • The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
  • The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
  • The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
  • The Nisonger child behavior rating form which allow to assess the behavior disorders
  • Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
  • Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical phenotyping of neurodevelopment: acquisition age of early developmental skills (motor and language), and the adaptive skills profile (Vineland adaptive behavioral scale)
Time Frame: at inclusion (Day 1)
The primary outcome measure is composite and includes acquisition age of early developmental skills (motor and language), and the adaptive skills profile (Vineland adaptive behavioral scale). The Vineland adaptive behavioral scale performed during a semi-structured interview of the parents of the patient, will assess the adaptive behavior profile of the patient (including communication, daily living skills, socialization, motricity and the global adaptive score).
at inclusion (Day 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intellectual functioning assessment (Wechsler scale)
Time Frame: at inclusion (Day 1)
The Intellectual Quotient of the patient will be assessed using a Wechsler scale, adapted to the age of the patient. For patients younger than 3 years or too severely impaired to perform a Wechsler scale, the Brunet Lézine scale will be used.
at inclusion (Day 1)
Raven's Progressive matrices
Time Frame: at inclusion (Day 1)
The Raven's Progressives matrices test will allow to assess the non-verbal reasoning mental age of the patient
at inclusion (Day 1)
Peabody Picture Vocabulary Test Revised
Time Frame: at inclusion (Day 1)
The Peabody Picture Vocabulary Test Revised will allow to determine the Vocabulary age (receptive language) of the patient.
at inclusion (Day 1)
Edinburgh handedness test
Time Frame: at inclusion (Day 1)
The Edinburgh handedness test will assess the handedness of the patients.
at inclusion (Day 1)
Birth parameters: weight, height and head circumference and APGAR score
Time Frame: at inclusion (Day 1)
The birth parameters include weight, height and head circumference at birth, as well as the initial cardiac and pulmonary adaptation (APGAR score).
at inclusion (Day 1)
Nisonger child behavior rating form
Time Frame: at inclusion (Day 1)
The Nisonger child behavior rating form will allow the assessment of behavior disorders including: conduct disorders, anxiety, hyperactivity, automutilation/stereotyped behavior, self-isolation/rituals, sensitivity/susceptibility.
at inclusion (Day 1)
Caregiver Burden Inventory Modified
Time Frame: at inclusion (Day 1)
The Caregiver Burden Inventory Modified will allow the assessment of the impact of mental retardation on the primary caregiver within the family.
at inclusion (Day 1)
Analogical visual reasoning task (behavior assessment)
Time Frame: at inclusion (Day 1)
This paradigm (HCL/CNRS patented), appropriate for mentally retarded patients provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
at inclusion (Day 1)
Analogical visual reasoning task (eye-tracking assessment)
Time Frame: at inclusion (Day 1)
The eye-tracking analysis of this paradigm (HCL/CNRS patented) made it possible to identify the strategy used by participants to solve the task. Mentally Retarded patients are not able to explicitly explain the strategy they used to solve the task, but with eye-tracking analysis, we can understand how they performed the task, which is crucial information in order to help them improve their performance through remediation strategies.
at inclusion (Day 1)
Kinematic analysis of a grasping movement
Time Frame: at inclusion (Day 1)
This kinematic analysis of a grasping movement will allow us to study the effect of the orientation (+56°or -56°) and the type of pinch (thumb-index, thumb-middle finger and thumb-annular) on the movement duration and both the transport component (wrist acceleration and velocity peaks, latencies and amplitudes) and the grasp component (maximum grip aperture latency and amplitude and opposition axis).
at inclusion (Day 1)
Structural neuroimaging by MRI
Time Frame: at inclusion (Day 1)
Structural brain MRI analysis will determine if a specific morphological neuroanatomical pattern can be found for each X-linked mental retardation gene.
at inclusion (Day 1)
Functional neuroimaging by MRI
Time Frame: at inclusion (Day 1)
Functional brain MRI analysis will determine if patients with X-linked mental retardation have a specific functional neuroanatomical pattern associated to the reasoning task.
at inclusion (Day 1)
School curriculum: age and type of shool
Time Frame: at inclusion (Day 1)
The school curriculum will include the age at school entrance, and the type of school the child went to.
at inclusion (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vincent DESPORTES, Pr, Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de neurologie pédiatrique

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2011

Primary Completion (Actual)

December 1, 2015

Study Completion (Anticipated)

March 31, 2018

Study Registration Dates

First Submitted

June 29, 2016

First Submitted That Met QC Criteria

July 31, 2016

First Posted (Estimate)

August 4, 2016

Study Record Updates

Last Update Posted (Actual)

July 12, 2017

Last Update Submitted That Met QC Criteria

July 11, 2017

Last Verified

July 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe